[…] the Research program for Neuromuscular Disorders. We hear that currently there is “no cure for FSHD,” but this does not mean there is no treatment. Treatment and cure are two […]
Treatments for FSHD: A broader view
Dyne ramps up its FSHD program
Dyne Therapeutics, a Waltham, Massachusetts, biopharmaceutical company, announced yesterday that it is accelerating its FSHD therapy development program. Here is their press release: Dyne to evaluate therapies targeting genetic cause […]
Recent FSHD research publications
[…] of DUX4, which is very important to understand if we are to attempt to treat FSHD by suppressing the unwanted negative effects of DUX4. * “Antisense Oligonucleotides Used to Target […]
BetterLife FSHD
Stay Updated: Join Our Mailing List Countdown to the BetterLife Launch Why join BetterLife FSHD? Ready to take charge of your FSHD journey? With every survey you complete and symptom […]
Q &A on potential use of BET inhibitors for FSHD
On February 13, Canadian biotech, Reserverlogix announced that facioscapulohumeral muscular dystrophy ( FSHD) is one of two new indications it is pursuing involving its lead drug, apabetalone (RVX-208) which inhibits […]